Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 5/20 | 1.00 |
| ▸ | SOS2 | Q07890 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | NCF1 | P14598 | 1/20 | 0.53 |
| ▸ | FERMT2 | Q96AC1 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CCR1 | P32246 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CHKA | P35790 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KMT5B | Q4FZB7 | 1/20 | 0.47 |
| ▸ | KMT5C | Q86Y97 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21101482 | 0.84 | NR4A2 (1.00) | NR4A2SOS2CYP1A2NCF1FERMT2 | |
| SCHEMBL16735795 | 0.83 | NR4A2 (0.70) | NR4A2SOS2CYP1A2FERMT2MAPT | |
| SCHEMBL317202 | 0.79 | NR4A2 (0.66) | NR4A2SOS2CYP1A2NCF1FERMT2 | |
| SCHEMBL29396540 | 0.79 | NR4A2 (0.66) | NR4A2SOS2CYP1A2NCF1FERMT2 | |
| SCHEMBL3073397 | 0.79 | NR4A2 (0.66) | NR4A2SOS2NCF1MAPTKMT2A | |
| SCHEMBL30044428 | 0.79 | NR4A2 (0.66) | NR4A2SOS2NCF1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL11519956 | 0.78 | NR4A2 (0.63) | NR4A2SOS2CYP1A2NCF1FERMT2 | |
| Bromide SCHEMBL1611915 | 0.78 | NR4A2 (0.63) | NR4A2SOS2CYP1A2NCF1FERMT2 | |
| Bromide SCHEMBL1611919 | 0.78 | NR4A2 (0.63) | NR4A2SOS2CYP1A2NCF1FERMT2 | |
| SCHEMBL11774891 | 0.76 | NR4A2 (0.61) | NR4A2SOS2CYP1A2NCF1FERMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114933562-B | Efficient preparation method of chloroquine based on (2-hydroxybenzyl) disubstituted phosphine oxide catalysis | 华东理工大学 | 2024-07-23 | — | — | CN | claimed |
| EP-3481806-B1 | 4-ANILINO-QUINOLINE COMPOUNDS AS ANTI-CANCER AGENTS | INST NAT SANTE RECH MED (FR) | 2023-06-07 | — | — | EP | claimed |
| CN-114933562-A | Efficient preparation method of chloroquine based on catalysis of (2-hydroxybenzyl) disubstituted phosphine oxide | 华东理工大学 | 2022-08-23 | — | — | CN | claimed |
| CN-110862345-B | Preparation method of salazosulfapyridine intermediate | 苏州黄河制药有限公司 | 2022-03-11 | — | — | CN | claimed |
| EP-3675814-A1 | COMPOSITION FOR TOPICAL TREATMENT OF NON-MICROORGANISM-CAUSED INFLAMMATORY SKIN AND MUCOUS-MEMBRANE DISEASES | Bläss, Markus (DE) | 2020-07-08 | — | — | EP | claimed |
| CN-110862345-A | Preparation method of salazosulfapyridine intermediate | 苏州黄河制药有限公司 | 2020-03-06 | — | — | CN | claimed |
| CN-107266323-B | A kind of side chain and its synthetic method, and the method using side chain synthesis hydroxychloroquine sulfate | 宜宾莱特医药化工有限公司 | 2019-04-19 | — | — | CN | claimed |
| WO-2019043064-A1 | COMPOSITION FOR TOPICAL TREATMENT OF NON-MICROORGANISM-CAUSED INFLAMMATORY SKIN AND MUCOUS-MEMBRANE DISEASES | BLAESS MARKUS (DE) | 2019-03-07 | — | — | WO | claimed |
| CN-105693605-B | A kind of method of asymmetric synthesis of optical voidness (R)/(S) chloroquine | 西安科技大学 | 2017-12-22 | — | — | CN | claimed |
| CN-105693606-B | A kind of method of asymmetric synthesis of optical voidness (R)/(S) HCQ | 西安科技大学 | 2017-12-05 | — | — | CN | claimed |
| CN-101068821-A | Hybrid QA molecules where Q is an aminoquinoline and A is an antibiotic residue, their synthesis and use as antibacterial agents | PALUMED SA (FR) | 2007-11-07 | — | — | CN | claimed |
| WO-2007098047-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE | THE MCLEAN HOSPITAL CORPORATION (US) | 2007-08-30 | — | — | WO | claimed |
| EP-1771456-A2 | HYBRID QA MOLECULES WHEREIN Q IS AN AMINOQUINOLINE AND A IS AN ANTIBIOTIC RESIDUE, THEIR SYNTHESIS AND THEIR USES AS ANTIBACTERIAL AGENT | Palumed SA (FR) | 2007-04-11 | — | — | EP | claimed |
| US-20070060558-A1 | Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents | PALUMED S.A. (FR) | 2007-03-15 | — | — | US | claimed |
| WO-2006024741-A2 | HYBRID QA MOLECULES WHEREIN Q IS AN AMINOQUINOLINE AND A IS AN ANTIBIOTIC RESIDUE, THEIR SYNTHESIS AND THEIR USES AS ANTIBACTERIAL AGENT | PALUMED S.A. (FR) | 2006-03-09 | — | — | WO | claimed |
| WO-2003078436-A1 | PORPHYRIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2003-09-25 | — | — | WO | claimed |
| EP-0998946-A1 | Non-porphyrin compound for use as a diagnosticum and/or pharmaceutical | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2000-05-10 | — | — | EP | claimed |
| WO-2000009169-A1 | NON-PORPHYRIN COMPOUND FOR USE AS A DIAGNOSTICUM AND/OR PHARMACEUTICAL | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2000-02-24 | — | — | WO | claimed |
| US-5736557-A | MICROBIOCIDE EFFECTIVE AGAINST CHLOROQUINE-RESISTANT AND CHLOROQUINE-SENSITIVE STRAINS OF PLASMODIUM FALCIPARUM | HOFFMAN-LA ROCHE, INC. (US) | 1998-04-07 | — | — | US | claimed |
| EP-0056766-B1 | PROCESS FOR THE PREPARATION OF 4-AMINO-CHLOROQUINOLINES | RHONE-POULENC SANTE (FR) | 1984-05-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060558-A1 | Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents | QARS1, QPCT, QTRT2 | NR4A2 3836/4885SOS2 3006/4885CYP1A2 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.